Please login to the form below

Not currently logged in
Email:
Password:

Celesio still has claws in Protek despite delays

The EU's largest drug distributor, Celesio, is continuing to pursue a majority stake in Russian drug company Protek, despite a delay in the process

German-headquartered Celesio, the EU's largest drug distributor, is continuing to pursue a majority stake in Russian drug company Protek, despite a delay in the process, according to CEO Fritz Oesterle.

Oesterle said the delay was due to uncertainty concerning a possible nationalisation of one of Russia's top three pharmaceuticals companies, of which Protek is one, before the Russian elections earlier this month.

The speculation, although now diminished, now means that no deal would complete this year, according to Oesterle, who added that the transaction was not in jeopardy.

He said in a press statement on 12 December that if the company had the chance to get more information in the next two months then it would seize it.

When Celesion revealed the deal in October, it said it expected negotiations to be completed by mid-December. Oesterle also said Celesio was on the lookout for acquisitions in eastern Europe in 2008.

16th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics